Corbus' CRB-913 shows 5% mean weight loss at 12 weeks in Phase 1b trial
CRBP•Corbus said its oral obesity drug CRB-913 produced 5% mean weight loss at 12 weeks in a Phase 1b trial, with statistically significant weight loss across all tested doses.
1. Trial results
Corbus Pharmaceuticals presented results from its Phase 1b CANYON-1 trial of oral obesity drug CRB-913 at ObesityWeek 2026. The drug showed 5% mean weight loss at 12 weeks, with statistically significant, clinically meaningful weight loss across all tested doses and no plateau observed.
2. Safety and next steps
Psychiatric adverse events were mostly mild and resolved; no serious or severe psychiatric events were reported. Corbus plans discussions with the FDA about further development and is evaluating potential combinations with GLP-1 therapies.




